See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Effect of ensitrelvir on Long COVID in patients with mild-to-moderate COVID-19: A post-hoc analysis of the phase 3 SCORPIO-SR study
Effect of ensitrelvir on Long COVID in patients with mild-to-moderate COVID-19: A post-hoc analysis of the phase 3 SCORPIO-SR study
Effectiveness of cefiderocol in immunosuppressed patients with serious Gram-negative bacterial infections in the PERSEUS study in Spain
Effectiveness of cefiderocol in immunosuppressed patients with serious Gram-negative bacterial infections in the PERSEUS study in Spain
Effectiveness of cefiderocol in patients with intra-abdominal infections caused by Gram-negative bacteria in the PERSEUS study in Spain
Effectiveness of cefiderocol in patients with intra-abdominal infections caused by Gram-negative bacteria in the PERSEUS study in Spain
Efficacy and safety of ensitrelvir in non-hospitalized adults at standard or high risk of progression to severe COVID-19: the SCORPIO-HR phase 3, randomized, double-blind, placebo-controlled trial
Efficacy and safety of ensitrelvir in non-hospitalized adults at standard or high risk of progression to severe COVID-19: the SCORPIO-HR phase 3, randomized, double-blind, placebo-controlled trial
Ensitrelvir as a treatment option for persistent SARS-CoV-2 infection after remdesivir in hospitalized patients with comorbidities: A single-Center Case Series from Japan
Ensitrelvir as a treatment option for persistent SARS-CoV-2 infection after remdesivir in hospitalized patients with comorbidities: A single-Center Case Series from Japan
Ensitrelvir for asymptomatic and mild symptoms only: COVID-19 patients in phase 2b/3 Part
Ensitrelvir for asymptomatic and mild symptoms only: COVID-19 patients in phase 2b/3 Part
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
